Meanwhile, TD Cowen increased its price target to $120 from $110, with a Hold rating, citing the strong Comirnaty sales. In contrast, Wells Fargo adjusted its price target to $150 from $170, reflecting model updates related to BioNTech's collaboration with Bristol Myers Squibb, but maintained an Overweight rating. These developments highlight the mixed analyst perspectives on BioNTech's financial outlook. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.